Related Experiment Video

Updated: Mar 15, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

NAD+ Kinase as a Therapeutic Target in Cancer

Philip M Tedeschi1, Nitu Bansal1, John E Kerrigan1

  • 1Departments of Medicine and Pharmacology, Rutgers Robert Wood Johnson Medical School, the Rutgers Cancer Institute of New Jersey, and the Rutgers Graduate School of Biomedical Sciences, New Brunswick, New Jersey.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 2, 2016
PubMed

Insights

NAD+ kinase (NADK) is a promising cancer target. Inhibiting NADK with thionicotinamide may offer a new therapeutic strategy for cancer by disrupting essential metabolic pathways and reactive oxygen species neutralization.

Area of Science:

  • Biochemistry
  • Oncology
  • Drug Discovery

Background:

  • NAD+ kinase (NADK) produces NADP+, which is reduced to NADPH.
  • NADPH is crucial for biosynthesis and neutralizing reactive oxygen species (ROS).
  • Cancer cells have a high demand for NADPH to support proliferation and manage ROS.

Purpose of the Study:

  • To review evidence supporting NADK as a cancer therapeutic target.
  • To discuss the role of NADK in cancer metabolism and ROS regulation.
  • To present studies on thionicotinamide, an NADK inhibitor prodrug.

Main Methods:

  • In vitro and in vivo tumor growth assays.
  • Analysis of patient samples.
  • Evaluation of thionicotinamide as an NADK inhibitor.

Main Results:

  • NADK is identified as a potential therapeutic target in cancer.
  • NADK plays a key role in cancer cell metabolism and ROS management.
  • Thionicotinamide shows promise as an NADK inhibitor prodrug.

Conclusions:

  • Experimental evidence supports targeting NADK for cancer therapy.
  • NADK inhibition presents a viable strategy for cancer treatment.
  • Thionicotinamide warrants further investigation as a clinical cancer drug.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K